Core Insights - InterCure has announced the strategic acquisition of Botanico Ltd. (ISHI), enhancing its access to advanced cultivation technologies and premium American cannabis brands, coinciding with potential regulatory changes in the U.S. cannabis market [1][4] - The acquisition is expected to provide InterCure with immediate access to award-winning cannabis genetics and operational technologies, positioning the company to capitalize on evolving regulatory frameworks favoring compliant operators [2][4] Company Overview - InterCure Ltd. (dba Canndoc) is recognized as the leading and fastest-growing cannabis company outside North America, with a focus on pharmaceutical-grade medical cannabis products and a vertically integrated "seed-to-sale" model [7] Acquisition Details - The acquisition of ISHI involves a two-phase structure, with 50% of equity acquired initially for 2,467,055 InterCure ordinary shares, and the remaining 50% contingent on ISHI achieving positive operating profitability or within 24 months [5] - The total consideration for the acquisition amounts to 4,924,261 ordinary shares, representing approximately 10% of InterCure's outstanding shares on a fully diluted basis [5] Strategic Partnerships - ISHI has established exclusive partnerships with top-tier U.S. cannabis brands, including The Flowery, which operates significant cultivation and retail facilities in Florida and New York [2][6] - The acquisition is expected to enhance InterCure's supply chain and distribution operations, supporting its expansion into international markets where pharmaceutical-grade standards are becoming the benchmark [5][6] Regulatory Context - The acquisition aligns with the reported momentum in the U.S. regarding potential cannabis rescheduling, which could unlock significant opportunities for international cannabis companies like InterCure [1][4]